The molecular substrates associated with neuronal aging and the death of massive numbers of subsets of neurons in idiopathic Parkinson's disease (PD) with and without dementia, and Alzheimer's disease (AD) with and without parkinsonism remain poorly characterized. Although the etiology of AD and PD may be multifactorial, and several pathways may lead to the selective, but massive loss of neurons in AD and PD, a detailed characterization of the molecular abnormalities that occur in association with the death of neurons represents important first steps in elucidating the mechanisms whereby neurons degenerate in these 2 distinct neurodegenerative conditions. This information also could provide a rational strategy for the discovery of clinical interventions as well as for the identification of early and specific markers of AD and PD. Accordingly, this Program Project will identify and characterize molecular disturbances in defined populations of central nervous system neurons (e.g. neurons in basal ganglia, brainstem, hippocampus, and olfactory epithelium) that degenerate in large numbers and thereby contribute to the extra- pyramidal deficits, memory loss and diminished olfaction observed in patients with PD and AD. To do this, a Clinical Core has been established to examine controls and patients with PD and/or AD bi-annually, and to develop """"""""step-down"""""""" procedures for monitoring patients with end stage disease. The tissues from subjects studies in the Clinical Core who come to autopsy will be assessed diagnostically by the Neuropathology Core which also will evaluate the potential specificity of novel olfactory epithelium lesions for AD, and distribute well characterized tissue samples to Project investigators. Using molecular probes (monoclonal antibodies, cDNAs) and postmortem tissues the following peptides and polypeptides will be examined in this Program Project: D1 and D2 dopamine receptors (Project 1); Senile plaque beta-amyloid peptides, their precursors and the tau and neurofilament components in plaque coronas (Project 2); Kinases that act on neuronal cytoskeletal proteins especially tau (Project 3). The peptides and proteins to be studied here have been clearly implicated in altered dopamine innervation, the formation of newly discovered neuritic in altered dopamine innervation, the formation of newly discovered neuritic pathology in Ad olfactory epithelium, and some of the hallmark lesions of PD and AD (e.g. senile plaques and other accumulations of amyloid and cytoskeletal protein fragments). Thus, this Program Project represents a comprehensive effort to characterize the molecular pathology of these lesions, and probe mechanisms whereby they arise and contribute to neuron death.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG009215-04
Application #
3091254
Study Section
Aging Review Committee (AGE)
Project Start
1990-08-01
Project End
1995-04-30
Budget Start
1993-05-01
Budget End
1994-04-30
Support Year
4
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
Schools of Medicine
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Tosto, Giuseppe; Monsell, Sarah E; Hawes, Stephen E et al. (2015) Pattern of extrapyramidal signs in Alzheimer's disease. J Neurol 262:2548-56
Paumier, Katrina L; Luk, Kelvin C; Manfredsson, Fredric P et al. (2015) Intrastriatal injection of pre-formed mouse ?-synuclein fibrils into rats triggers ?-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol Dis 82:185-199
Kalia, Lorraine V; Lang, Anthony E; Hazrati, Lili-Naz et al. (2015) Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 72:100-5
Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2014) APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 71:1405-12
Motsinger-Reif, Alison A; Zhu, Hongjie; Kling, Mitchel A et al. (2013) Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging. Acta Neuropathol Commun 1:28
Arnold, Steven E; Toledo, Jon B; Appleby, Dina H et al. (2013) Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. J Comp Neurol 521:4339-55
Kaddurah-Daouk, R; Zhu, H; Sharma, S et al. (2013) Alterations in metabolic pathways and networks in Alzheimer's disease. Transl Psychiatry 3:e244
Couthouis, Julien; Hart, Michael P; Erion, Renske et al. (2012) Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum Mol Genet 21:2899-911
Hu, William T; Holtzman, David M; Fagan, Anne M et al. (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79:897-905
Chen-Plotkin, Alice S; Unger, Travis L; Gallagher, Michael D et al. (2012) TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J Neurosci 32:11213-27

Showing the most recent 10 out of 208 publications